½ÃÀ庸°í¼­
»óǰÄÚµå
1703444

¼¼°èÀÇ Ä«¸£ºñµµÆÄ(arbidopa) ½ÃÀå :½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Çâ, ±âȸ, ¿¹Ãø, ÆÇ¸Åä³Îº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, °æÀﺰ(2020-2030³â)

Carbidopa Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region and Competition, 2020-2030F

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: TechSci Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 185 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è Ä«¸£ºñµµÆÄ ½ÃÀåÀº 2024³â 4¾ï 7,512¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2030³â¿¡´Â 6¾ï 8,965¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 7.99%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ÆÄŲ½¼º´ ¹× ±âŸ ½Å°æ°è Áúȯ °ü·Ã Ä¡·á¿¡ ´ëÇÑ Àü ¼¼°è ¼ö¿ä Áõ°¡ÀÔ´Ï´Ù.

½ÃÀå °³¿ä
¿¹Ãø ±â°£ 2026-2030³â
½ÃÀå ±Ô¸ð : 2024³â 4¾ï 7,512¸¸ ´Þ·¯
½ÃÀå ±Ô¸ð : 2030³â 6¾ï 8,965¸¸ ´Þ·¯
CAGR : 2025-2030³â 7.99%
±Þ¼ºÀå ºÎ¹® °£Á¢ ºÎ¹®
ÃÖ´ë ½ÃÀå ºÏ¹Ì

Ä®ºñµµÆÄ´Â ·¹º¸µµÆÄÀÇ »ýü ÀÌ¿ë·ü°ú Ä¡·á È¿°ú¸¦ Çâ»ó½ÃÅ´À¸·Î½á º´¿ë¿ä¹ý(ƯÈ÷ ·¹º¸µµÆÄ¿ÍÀÇ º´¿ë¿ä¹ý)¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è Àα¸ÀÇ °í·ÉÈ­¿Í ÆÄŲ½¼º´ ¹ßº´·ü Áõ°¡·Î ÀÎÇØ È¿°úÀûÀ̰í Àå±âÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 ½ÃÀå È®´ë°¡ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

°æÀï ±¸µµÀ¸·Î´Â ´Ù±¹Àû Á¦¾à±â¾÷°ú Áö¿ª Á¦Á¶¾÷üµéÀÌ »óȲ¿¡ ¸Â´Â Ä¡·áÁ¦ÀÇ °³¹ß, »ý»ê, »ó¾÷È­¿¡ Àû±Ø ³ª¼­°í ÀÖ½À´Ï´Ù. ¿¬±¸°³¹ß¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀڴ ƯÈ÷ ¼­¹æÈ­ ±â¼ú ¹× ¹æÃâ Á¦¾î ±â¼úÀ» ÅëÇÑ ¾à¹° Á¦Á¦ÀÇ ÃÖÀûÈ­¿¡ ÁßÁ¡À» µÎ¾î Ä¡·á¼ºÀûÀÇ Çâ»ó°ú ºÎÀÛ¿ëÀÇ °¨¼Ò¸¦ µµ¸ðÇϰí ÀÖ½À´Ï´Ù. Àü·«Àû ÆÄÆ®³Ê½Ê, ÇÕº´, ÀÇ·á±â°ü°úÀÇ Á¦ÈÞ´Â ½ÃÀå ³» ±â¼ú Çõ½Å°ú °æÀï·ÂÀ» ´õ¿í °­È­Çϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ

¼¼°è ÇコÄÉ¾î ºÎ¹® È®´ë

ÁÖ¿ä ½ÃÀå À̽´

ºÎÀÛ¿ë°ú ¾ÈÀü¿¡ ´ëÇÑ ¿ì·Á

ÁÖ¿ä ½ÃÀå µ¿Çâ

º´¿ë¿ä¹ý µµÀÔ Áõ°¡

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå COVID-19°¡ ¼¼°èÀÇ Ä«¸£ºñµµÆÄ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâ

Á¦5Àå ¼¼°èÀÇ Ä«¸£ºñµµÆÄ ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø
    • ±Ý¾×º°
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
    • ÆÇ¸Åä³Îº°(Á÷Á¢, °£Á¢)
    • ¿ëµµº°(Ư¹ß¼º ÆÄŲ½¼º´, ³ú¿° ÈÄ ÆÄŲ½¼º´, ÁõÈļº ÆÄŲ½¼º´, ±âŸ)
    • Áö¿ªº°
    • ±â¾÷º°(2024³â)
  • ½ÃÀå ¸Ê

Á¦6Àå ºÏ¹ÌÀÇ Ä«¸£ºñµµÆÄ ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
  • ºÏ¹Ì : ±¹°¡º° ºÐ¼®
    • ¹Ì±¹
    • ¸ß½ÃÄÚ
    • ij³ª´Ù

Á¦7Àå À¯·´ÀÇ Ä«¸£ºñµµÆÄ ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
  • À¯·´ : ±¹°¡º° ºÐ¼®
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Ä«¸£ºñµµÆÄ ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
  • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º° ºÐ¼®
    • Áß±¹
    • Àεµ
    • Çѱ¹
    • ÀϺ»
    • È£ÁÖ

Á¦9Àå ³²¹ÌÀÇ Ä«¸£ºñµµÆÄ ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
  • ³²¹Ì : ±¹°¡º° ºÐ¼®
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ÄÝ·Òºñ¾Æ

Á¦10Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Ä«¸£ºñµµÆÄ ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º° ºÐ¼®
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)

Á¦11Àå ½ÃÀå ¿ªÇÐ

  • ¼ºÀå ÃËÁø¿äÀÎ
  • °úÁ¦

Á¦12Àå ½ÃÀå µ¿Çâ°ú ¹ßÀü

  • ÀμöÇÕº´(M&A)
  • Á¦Ç° Ãâ½Ã
  • ÃÖ±Ù µ¿Çâ

Á¦13Àå ¼¼°èÀÇ Ä«¸£ºñµµÆÄ ½ÃÀå : SWOT ºÐ¼®

Á¦14Àå PorterÀÇ Five Forces ºÐ¼®

  • ¾÷°è³» °æÀï
  • ½Å±Ô Âü¿© °¡´É¼º
  • °ø±Þ¾÷üÀÇ Èû
  • °í°´ÀÇ Èû
  • ´ëüǰÀÇ À§Çù

Á¦15Àå °æÀï ±¸µµ

  • Smruthi Organics Ltd.
  • Zhejiang Yefeng Pharmaceutical Co., Ltd
  • Divi's Laboratories Limited
  • GreenSyn Life Science
  • Xi'an D-Sung Biotechnology Co., Ltd.
  • Hetero Drugs limited
  • Hangzhou Dingyan Chem Co.,Ltd
  • Zhejiang Yongtai Chiral Pharmaceutical Technology Co., Ltd.
  • Xi'an Yihui Bio-technology Co., Ltd
  • Hanhong Medicine Technology(hubei) co. Ltd

Á¦16Àå Àü·«Àû Á¦¾È

Á¦17Àå ¸®¼­Ä¡»ç¿¡ ´ëÇØ & ¸éÃ¥»çÇ×

LSH 25.04.25

Global Carbidopa Market was valued at USD 475.12 million in 2024 and is projected to reach USD 689.65 million by 2030, expanding at a compound annual growth rate (CAGR) of 7.99% during the forecast period. Market growth is being driven by the rising global demand for treatments related to Parkinson's disease and other neurological conditions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 475.12 Million
Market Size 2030USD 689.65 Million
CAGR 2025-20307.99%
Fastest Growing SegmentIndirect
Largest MarketNorth America

Carbidopa plays a critical role in combination therapies-most notably with levodopa-by increasing levodopa's bioavailability and therapeutic efficacy. As the global population continues to age and the incidence of Parkinson's disease rises, the demand for effective, long-term treatment options is accelerating market expansion.

The competitive landscape includes both multinational pharmaceutical companies and regional manufacturers actively engaged in the development, production, and commercialization of carbidopa-based therapies. Significant investments in research and development are focused on optimizing drug formulations, particularly through extended-release and controlled-release technologies, to enhance treatment outcomes and reduce adverse effects. Strategic partnerships, mergers, and collaborations with healthcare institutions are further driving innovation and competitive positioning within the market.

Key Market Drivers

Expansion of the Global Healthcare Sector

The global growth of the healthcare industry is a major driver for the carbidopa market. Healthcare accounts for a significant share of GDP in developed economies-surpassing 10% in many countries. For instance, in the United States, healthcare expenditure reached USD 4.3 trillion in 2021, equating to USD 12,914 per capita, reflecting a 2.7% year-over-year increase.

Carbidopa is widely used in the treatment of Parkinson's disease and related neurodegenerative conditions. As healthcare infrastructure improves and demand for chronic disease management rises, carbidopa's role as an essential pharmaceutical agent has become increasingly prominent.

Key Market Challenges

Side Effects and Safety Concerns

Despite its clinical value, one of the primary challenges hindering market growth is the range of side effects associated with carbidopa-based therapies. While the combination of carbidopa and levodopa remains a cornerstone in Parkinson's disease treatment, patients often experience side effects such as nausea, dizziness, orthostatic hypotension, and dyskinesia. These can significantly impact quality of life and treatment adherence.

Moreover, long-term use may lead to motor fluctuations, characterized by alternating "on" periods-when the medication is effective-and "off" periods-when symptoms return. These complications can make disease management more difficult and reduce the effectiveness of therapy over time, thereby posing a barrier to wider market adoption.

Key Market Trends

Rising Adoption of Combination Therapies

A notable trend in the carbidopa market is the growing use of combination therapies, particularly with levodopa. The carbidopa-levodopa pairing remains the gold standard for managing motor symptoms of Parkinson's disease. Furthermore, newer formulations such as the levodopa/carbidopa/entacapone triple combination infusion-already launched in select European markets-are gaining traction. Early feedback indicates that patients can transition from traditional jejunal levodopa infusion to this novel therapy with relative ease.

Key Market Players

  • Smruthi Organics Ltd.
  • Zhejiang Yefeng Pharmaceutical Co., Ltd
  • Divi's Laboratories Limited
  • GreenSyn Life Science
  • Xi'an D-Sung Biotechnology Co., Ltd.
  • Hetero Drugs limited
  • Hangzhou Dingyan Chem Co.,Ltd
  • Zhejiang Yongtai Chiral Pharmaceutical Technology Co., Ltd.
  • Xi'an Yihui Bio-technology Co., Ltd
  • Hanhong Medicine Technology (hubei) co. Ltd

Report Scope

In this report, the Global Carbidopa Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Carbidopa Market, By Sales Channel:

  • Direct
  • Indirect

Carbidopa Market, By End Use:

  • Idiopathic Parkinson Disease
  • Postencephalitic Parkinsonism
  • Symptomatic Parkinsonism
  • Others

Carbidopa Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Carbidopa Market.

Available Customizations:

Global Carbidopa Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Carbidopa Market

5. Global Carbidopa Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Idiopathic Parkinson Disease, Postencephalitic Parkinsonism, Symptomatic Parkinsonism, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Carbidopa Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Carbidopa Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Mexico Carbidopa Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Canada Carbidopa Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Carbidopa Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Carbidopa Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. Germany Carbidopa Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Carbidopa Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Carbidopa Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Carbidopa Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Carbidopa Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Carbidopa Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Carbidopa Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. South Korea Carbidopa Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. Japan Carbidopa Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Carbidopa Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. South America Carbidopa Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Carbidopa Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. Argentina Carbidopa Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. Colombia Carbidopa Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. Middle East and Africa Carbidopa Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Carbidopa Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Saudi Arabia Carbidopa Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. UAE Carbidopa Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Carbidopa Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Smruthi Organics Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Zhejiang Yefeng Pharmaceutical Co., Ltd
  • 15.3. Divi's Laboratories Limited
  • 15.4. GreenSyn Life Science
  • 15.5. Xi'an D-Sung Biotechnology Co., Ltd.
  • 15.6. Hetero Drugs limited
  • 15.7. Hangzhou Dingyan Chem Co.,Ltd
  • 15.8. Zhejiang Yongtai Chiral Pharmaceutical Technology Co., Ltd.
  • 15.9. Xi'an Yihui Bio-technology Co., Ltd
  • 15.10. Hanhong Medicine Technology (hubei) co. Ltd

16. Strategic Recommendations

17. About Us & Disclaimer

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦